ライフサイエンスコーパス: DARPP-32

1 e and cAMP-regulated phosphoprotein, 32 kDa (DARPP-32).

2 with striatal D1 versus D2 pathway balance (DARPP-32).

3 and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).

4 and cAMP-regulated phosphoprotein Mr 32kDa (DARPP-32).

5 s by a novel mechanism that does not require DARPP-32.

6 x signal transduction pathways that regulate DARPP-32.

7 ephosphorylation of Thr-75, the Cdk5 site in DARPP-32.

8 /Akt does not entirely abolish expression of DARPP-32.

9 2+)-dependent dephosphorylation at Thr-75 of DARPP-32.

10 y asking what specific cell subtypes contain DARPP-32.

11 1 has been found to phosphorylate Ser-137 of DARPP-32.

12 sphotyrosine-containing substrate or phospho-DARPP-32.

13 was blocked by antisense oligonucleotides to DARPP-32.

14 letely counteracts CS1 inhibition by I-2 and DARPP-32.

15 ctivity, phosphorylating both the InsP3R and DARPP-32.

16 neurotransmission converging on the protein DARPP-32.

17 for maximal inhibition of beta CaN using PO4-DARPP-32(20-38) as substrate.

18 a isoform (CnA beta) toward the PO4-RII, PO4-DARPP-32(20-38) peptides, and p-nitrophenylphosphate (pN

19 ',5'-monophosphate-regulated phosphoprotein (DARPP-32) (30%).

20 mediated phosphorylation of GluA1 Ser845 and DARPP-32 (32 kDa DA- and cAMP-regulated phosphoprotein)

21 dopamine- and cAMP-regulated phosphoprotein (DARPP-32), a potent and selective inhibitor of protein p

22 and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), a protein kinase A (PKA)-activated and calcin

23 DARPP-32, a dopamine- and adenosine 3',5'-monophosphate

24 volves control of PP-1 catalytic activity by DARPP-32, a dopamine- and cAMP-regulated phosphoprotein

25 A polymorphism in DARPP-32, a gene linked to dopaminergic striatal plastic

26 Here we show that DARPP-32, a hub signalling protein in striatal neurons,

27 the forebrain, as well as phosphorylation of DARPP-32, a phosphoprotein associated with activation of

28 ions, the amount of phosphorylated activated DARPP-32, a potent inhibitor of protein phosphatase 1 th

29 Knocking down either Bcl-2 or DARPP-32 abrogates this feedback mechanism, resulting in

30 DARPP-32 activated phosphatidylinositol-3-kinase-AKT sig

31 DARPP-32 activation is thus an obligatory step in proges

32 triatal-signaling pathways (protein kinase A/DARPP-32, Akt/glycogen synthase kinase 3, and ERK) are i

33 e dopamine and cAMP-regulated phosphoprotein DARPP-32 also was required for the regulation of MAPK an

34 enes controlling striatal dopamine function, DARPP-32 (also called PPP1R1B) and DRD2, are associated

35 PKA-mediated dephosphorylation at Thr-75 in DARPP-32 (also cotransfected into HEK293 cells).

36 ic AMP-regulated phosphoprotein of MR 32000 (DARPP-32), also known as PPP1R1B, is located together wi

37 The percentage increases to 25% for DARPP-32 and 10% for ARPP-21 when the same cells are gro

38 These results identify DARPP-32 and AMPA-type glutamate receptors as likely ess

39 A majority of MSNs coexpress DARPP-32 and ARPP-21, two dopamine and cyclic AMP-regula

40 Bcl-2 docks DARPP-32 and CaN in a complex on the InsP3R, creating a

41 The association between DARPP-32 and EGFR was evaluated by immunofluorescence an

42 urotrophic factor (BDNF), a known inducer of DARPP-32 and Egr-1 expression, enhanced Egr-1 binding to

43 striatal synaptic strength, dephosphorylates DARPP-32 and GluA1, and results in a preferential remova

44 P levels and PKA-mediated phosphorylation of DARPP-32 and GluA1, leading to increased GluA1 trafficki

45 nduced activation of ERK and mTORC1 requires DARPP-32 and indicates the importance of the cAMP/DARPP-

46 n a large loss of sensitivity to thiophospho-DARPP-32 and inhibitor-2, and also resulted in a loss of

47 y and reduced the sensitivity to thiophospho-DARPP-32 and inhibitor-2.

48 Concomitant overexpression of mRNA for Darpp-32 and its truncated isoform t-Darpp was observed

49 Both DARPP-32 and neural plasticity regulator activity-regula

50 ecreased ability to increase phospho-Ser-137-DARPP-32 and phospho-Ser-831-GluR1.

51 exhibited increased levels of phospho-Thr34 DARPP-32 and phospho-Ser845 GluR1 after dopamine D1 rece

52 nt role in dopaminergic function through the DARPP-32 and related transduction pathways.

53 ncreased the phosphorylation states of Thr34-DARPP-32 and Ser845-GluR1, both in brain slices and in t

54 The expression of Darpp-32 and t-Darpp is associated with a potent antiapo

55 Expression of Darpp-32 and t-Darpp preserved the mitochondrial transme

56 When Darpp-32 and t-Darpp were overexpressed in AGS and RKO g

57 as obtained using small interfering RNAs for Darpp-32 and t-Darpp.

58 taIII-tubulin(+) neurons, which developed as DARPP-32(+) and GABAergic medium spiny neurons that expr

59 amine- and cAMP-regulated phosphoprotein-32 (DARPP-32) and appears critical for the sensitization of

60 ne and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and blunted induction of immediate early genes

61 ine and cAMP-regulated phosphoprotein-32 kD (DARPP-32) and NMDA receptor subunit-1 (NR1)-NMDA recepto

62 cAMP-regulated phosphoprotein, M(r) 32 kDA (DARPP-32) and other dopamine-regulated phosphoprotein ma

63 major DARPP-32 transcripts, full-length (FL-DARPP-32) and truncated (t-DARPP-32), with genetic varia

64 mRNA and DARPP-32 immunoreactivity (IR), or DARPP-32- and CREB-IR in the same tissue sections.

65 aFosB, and the protein phosphatase inhibitor DARPP-32; and late-afternoon plasma corticosterone conce

66 MP-regulated neuronal phosphoprotein 32 kDa [DARPP-32], and cAMP responsive element binding protein s

67 d-type mice and mice lacking Inhibitor-1 and DARPP-32 as a result of targeted disruption of the genes

68 mice with alanine mutations introduced into DARPP-32 at either Thr34 (protein kinase A site, Thr34A)

69 seen in animals bearing a point mutation in DARPP-32 at the PKA (Thr34) but not at the casein kinase

70 n of fluoxetine increases phosphorylation of DARPP-32 at the protein kinase A site, Thr-34, and at th

71 Phosphorylation of DARPP-32 at Thr-34 by protein kinase A results in inhibi

72 accompanied by decreased phosphorylation of DARPP-32 at Thr-34.

73 A complex regulates the dephosphorylation of DARPP-32 at Thr-75, thereby helping coordinate the effic

74 The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the

75 ol group, the basal phosphorylation state of DARPP-32 at Threonine-34 site (pDARPP-32 Thr34) in the p

76 t kinase 5, and increased phosphorylation of DARPP-32 at threonine-34.

77 AMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippoc

78 lated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosph

79 on site for cAMP-dependent protein kinase on DARPP-32 attenuates l-DOPA-induced dyskinesia and reduce

80 demonstrate that two PP1 inhibitors, I-2 and DARPP-32, belong to the class of intrinsically unstructu

81 DARPP-32 binds to adducin MARCKS domain and this interac

82 MKN-28 cells, which do not normally express DARPP-32, blocked gefitinib-induced apoptosis and increa

83 y signaling pathways that are independent of DARPP-32 but require Fyn protein tyrosine kinase.

84 cyclic AMP-regulated phosphoprotein, 32 kDa (DARPP-32), but little is known about the mechanisms regu

85 1 in the interaction of PP1 with thiophospho-DARPP-32, but not inhibitor-2.

86 spase-3-positive cells express calbindin and DARPP-32, but not somatostatin, parvalbumin, or choliner

87 ether these results indicate that a CK1-Cdk5-DARPP-32 cascade may be involved in the regulation by mG

88 and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) cascade of enzymes that plays a central role i

89 DARPP-32 colocalized with EGFR on the cell membrane in a

90 The knockdown of endogenous DARPP-32 confirmed that DARPP-32 regulates the SRp20-dep

91 In striatal tissue from DARPP-32-depleted mice, basal tyrosine and serine phosph

92 377 samples was developed and used to detect DARPP-32 DNA amplification and protein overexpression, w

93 DARPP-32 (dopamine and adenosine 3', 5'-cyclic monophosp

94 DARPP-32 (dopamine and adenosine 3',5'-monophosphate-reg

95 Herein, we report that DARPP-32 (dopamine and cAMP-regulated phosphoprotein of

96 utamic acid decarboxylase, cabindin-D28, and DARPP-32 (dopamine and cAMP-regulated phosphoprotein of

97 P1) activity that appears to be mediated via DARPP-32 (dopamine and cAMP-regulated phosphoprotein) as

98 tion, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32

99 sphotyrosine-containing substrate or phospho-DARPP-32 (Dopamine and cAMP-regulated phosphoprotein, M(

100 triatum through phosphorylation of Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, mo

101 Herein, we investigated the role of DARPP-32 (dopamine and cyclic adenosine monophosphate-re

102 DARPP-32 (dopamine and cyclic AMP-regulated phospho-prot

103 rpp is a cancer-related truncated isoform of Darpp-32 (dopamine and cyclic-AMP-regulated phosphoprote

104 rea X cells expressing CaMKII also expressed DARPP-32 (dopamine- and adenosine 3'5'-monophosphate-reg

105 cade centered on the neuronal phosphoprotein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of

106 DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of

107 The phosphoprotein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein) h

108 of the CDK5 site of the postsynaptic protein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, m

109 tly inhibited by the phosphorylated forms of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, M

110 nlike those used by the cytosolic inhibitors DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, M

111 The current study determined activation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein-32

112 knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [

113 MP-regulated neuronal phosphoprotein 32 kDa (DARPP-32), dopamine receptors-1 and -2, alpha-2C- adreno

114 d phosphoprotein of molecular weight 32 kDa (DARPP-32), encoded by PPP1R1B, is a pivotal integrator o

115 reduction in the expression of key proteins (DARPP-32, ERK, and PP-1) belonging to this pathway, with

116 and cAMP-regulated neuronal phosphoprotein (DARPP-32) exclusively in D2R-expressing cells exhibited

117 In the striatum, these neurons were DARPP-32-expressing medium spiny neurons, consistent wit

118 We next examined DARPP-32 expression in the retina and intergeniculate le

119 criptional mechanisms that regulate striatal DARPP-32 expression remain enigmatic and are a subject o

120 Western immunoblot analysis revealed that p-DARPP-32 expression was greatest in the MPOA of males th

121 DARPP-32 expression was reduced using small hairpin RNAs

122 enesis, results in a significant increase in DARPP-32 expression.

123 ve performance were associated with higher t-DARPP-32 expression.

124 Phospho-Thr75-DARPP-32 facilitates beta-adducin Ser713 phosphorylation

125 hibits a strong spatial gradient, diffusible DARPP-32 facilitates the spread of PKA activity, suggest

126 of a large number of MSN markers, including DARPP-32, FOXP1, Chrm4, Reelin, MOR1 (mu-opioid receptor

127 changes in the levels of phosphorylation in DARPP-32 from the mouse striatum upon treatment of anima

128 reclinical work, there are almost no data on DARPP-32 function in humans.

129 tion, we have identified full-length cDNA of DARPP-32 (GenBank accession number AF464196) with 467 bp

130 zygous mice carrying a null mutation for the DARPP-32 gene exhibited minimal levels of P-facilitated

131 ated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecula

132 A polymorphism in the DARPP-32 gene, associated with striatal dopamine functio

133 cipitation and immunoblotting indicated that DARPP-32 has an important role in regulating SRp20 prote

134 Additionally, BrdU and DARPP-32 immunocytochemistry were combined to test wheth

135 ase mRNA was found in the cell bodies of all DARPP-32-immunolabeled tanycytes.

136 ere performed for type 2 deiodinase mRNA and DARPP-32 immunoreactivity (IR), or DARPP-32- and CREB-IR

137 Analysis of NeuN and DARPP-32 immunoreactivity, and Nissl staining, in the st

138 ice with a targeted deletion of the gene for DARPP-32 in a discriminated operant task using food rein

139 1-35), also antagonizes inhibition of CS1 by DARPP-32 in a pattern similar to that of I-2.

140 ucleus accumbens and increased expression of DARPP-32 in accumbens medium spiny neurons in a pattern

141 As RA promotes the expression of DARPP-32 in differentiating LGE cells in vitro, we exami

142 t mice, we demonstrated a regulatory role of DARPP-32 in dopamine-induced Ca(2+) oscillations.

143 Knockdown of DARPP-32 in gastric cancer cells reduced the mean size o

144 We investigated the role of DARPP-32 in gastric tumor resistance to gefitinib.

145 Overexpression of DARPP-32 in MKN-28 cells, which do not normally express

146 ngs establish for the first time the role of DARPP-32 in regulating splicing factors in gastric cance

147 Reduced expression of DARPP-32 in SNU-16 cells increased the sensitivity to ge

148 Our previous studies of DARPP-32 in striatal slices have shown that activation o

149 Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific i

150 Using these mice, we found that the loss of DARPP-32 in striatonigral neurons decreased basal and co

151 Conversely, the loss of DARPP-32 in striatopallidal neurons produced a robust in

152 ts provide evidence for a functional role of DARPP-32 in the mediation of processes underlying learni

153 tment with K252a attenuated the induction of DARPP-32 in the postweanling striatum.

154 cated (t-DARPP-32), with genetic variants of DARPP-32 in three brain regions receiving dopaminergic i

155 Cdk5 phosphorylates DARPP-32 in vitro and in intact brain cells.

156 ransduction pathways mediating expression of DARPP-32 in vitro, including a novel, important pathway

157 dopamine- and cAMP-regulated phosphoprotein (DARPP-32) in the MPOA of animals with acute and/or chron

158 DARPP-32 induction by BDNF in vitro requires phosphatidy

159 2, whereas a dominant-negative Egr-1 blocked DARPP-32 induction by BDNF.

160 Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanis

161 Phosphorylated DARPP-32 inhibits PP1, enhancing InsP3R phosphorylation

162 rylation of Thr(34) in DARPP-32, which turns DARPP-32 into a potent inhibitor of PP1, neither local n

163 All tanycytes containing DARPP-32-IR also contained CREB-IR in their nucleus.

164 Both type 2 deiodinase mRNA and DARPP-32-IR also extended into tanycyte processes that r

165 not present in the same cells that contained DARPP-32-IR in the pituitary gland.

166 Thus DARPP-32 is a bifunctional signal transduction molecule

167 DARPP-32 is a downstream marker of D(1) receptor signali

168 DARPP-32 is a dual-function protein kinase/phosphatase i

169 1, neither local nor long-range structure of DARPP-32 is altered.

170 We find that DARPP-32 is converted into an inhibitor of PKA when phos

171 Our data indicate that DARPP-32 is essential not only for dopaminergic but also

172 In this study we found that DARPP-32 is expressed in <12% of E13- or E17-derived str

173 The results indicate that DARPP-32 is involved in the retinal pathway transmitting

174 DARPP-32 is phosphorylated at multiple sites by differen

175 Here, we test whether DARPP-32 is required for sensitization of Drd1a response

176 ice, indicating that neither Inhibitor-1 nor DARPP-32 is required for the full stimulatory effects of

177 Using mice in which DARPP-32 is selectively deleted in D1R-expressing MSNs,

178 DARPP-32 is the most commonly used MSN marker, but previ

179 DARPP-32 is the only known protein that acts as a protei

180 te-regulated phosphatase inhibitor known as "DARPP-32" is present in rat, cat, monkey, and human reti

181 and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) is an important molecular target of the dopami

182 regulated phospho-protein of 32 kilodaltons (DARPP-32) is phosphorylated or dephosphorylated at three

183 hosphate-regulated phosphoprotein, Mr 32000 (DARPP-32), is overexpressed during gastric carcinogenesi

184 eference, and ethanol self-administration in DARPP-32 knock-out (KO) mice compared to wild-type (WT)

185 -32 regulation in the circadian system using DARPP-32 knock-out (KO) mice.

186 In both wild-type and DARPP-32 knock-out mice, Drd1a robustly induces pERK1/2

187 In experiments with MSN from DARPP-32 knock-out mice, we demonstrated a regulatory ro

188 d cAMP-regulated phosphoprotein M(r) 32 kDa (DARPP-32) knock-out mice.

189 Wild-type and DARPP-32 knockout mice exhibited equivalent performance

190 ere observed during the reversal phase, with DARPP-32 knockout mice requiring significantly more tria

191 Initially, wild-type and DARPP-32 knockout mice were trained to nose-poke for foo

192 depressant efficacy were strongly reduced in DARPP-32 knockout mice, indicating a critical role for t

193 NMDA receptors by D1 receptors was absent in DARPP-32 knockout mice.

194 ly release serotonin were greatly reduced in DARPP-32 knockout mice.

195 her butyrolactone or CK1-7 and was absent in DARPP-32 knockout mice.

196 dopamine- and cAMP-regulated phosphoprotein (DARPP-32+), known to be modulated by dopamine.

197 IM neurons in primates label for the protein DARPP-32, known to be activated or inhibited based on th

198 uced clock gene mPer2 were attenuated in the DARPP-32 KO mice.

199 are consistent with a selective reduction in DARPP-32 levels in schizophrenic subjects.

200 hologies in the striatum including decreased DARPP-32 levels, neurite degeneration of parvalbumin-con

201 ponses to cocaine and concurrently modulates DARPP-32 levels.

202 etinally sectioned or flat mounted and found DARPP-32-like immunoreactivity in some cells of the amac

203 cesses containing tyrosine hydroxylase, that DARPP-32-like immunoreactivity is present in AII amacrin

204 ograft mouse model, knocking down endogenous DARPP-32 markedly reduced SRp20 and CD44E protein levels

205 sults indicated that knockdown of endogenous DARPP-32 markedly reduces the expression of CD44 V8-V10

206 o proteins may coexist in tanycytes and that DARPP-32 may modulate type 2 deiodinase activity by regu

207 nces that increase cAMP, we hypothesize that DARPP-32 may regulate the activity of type 2 deiodinase

208 We propose that DARPP-32 mediated blunting of the response to ethanol su

209 ribute to the effects of cocaine on ERK- and DARPP-32-mediated cascades, on gene expression and on be

210 DARPP-32-mediated resistance to gefitinib resulted from

211 one and are recruited primarily as GABAergic DARPP-32+ medium spiny neurons in the caudate-putamen.

212 ll as with expression of prefrontal cortical DARPP-32 messenger RNA (mRNA) in a relatively small samp

213 ressive markers of MSN neurogenesis (Islet1, DARPP-32, mGluR1, and NeuN).

214 ffects the abundance of the splice variant t-DARPP-32 mRNA and may reflect potential molecular mechan

215 ated with fluoxetine had increased levels of DARPP-32 mRNA and protein and a decreased ability to inc

216 Cell extrinsic molecules that increase DARPP-32 mRNA and/or protein levels include brain-derive

217 Both Thr34A- and Ser130A-DARPP-32 mutant mice self-administered more cocaine than

218 By contrast, inhibition of DARPP-32 neurons in IM by high dopamine levels disinhibi

219 tants, but the disproportionate reduction in DARPP-32 neurons is not improved.

220 ent, including a smaller striatum with fewer DARPP-32 neurons than wild types.

221 The predominant pOFC innervation of DARPP-32+ neurons suggests activation of IM and inhibiti

222 such as Hdm2 and p21, indicated that neither Darpp-32 nor t-Darpp interfere with p53 function.

223 Thus, DARPP-32 occupies a key regulatory position, and may pla

224 we show that the abnormal phosphorylation of DARPP-32 occurs specifically in medium spiny neurons (MS

225 P also enhanced phosphorylation of DARPP-32 on threonine 34 in the hypothalamus of mice.

226 used no change in sensitivity to thiophospho-DARPP-32 or inhibitor-2, but one mutant (E252A:D253A:E25

227 d phosphoprotein of molecular weight 32 kDa (DARPP-32 or PPP1R1B) has been of interest in schizophren

228 In mice with a genetic deletion of DARPP-32 or with point mutations in phosphorylation site

229 increase in the reporter activity following DARPP-32 overexpression (P<0.001).

230 We show the molecular mechanisms involved in Darpp-32 overexpression and its biological role in upper

231 dopamine- and cAMP-regulated phosphoprotein (DARPP-32) pathways has been implicated in biochemical an

232 or PPP2R5D) regulatory subunit, is an active DARPP-32 phosphatase.

233 t of PP2A substrates including phospho-Thr75-DARPP-32, phospho-T308-Akt, and phospho-T202/Y204-ERK.

234 m were attenuated in the Thr34A- and Ser130A-DARPP-32 phosphomutant mice compared with wild-type mice

235 Here we report that serotonin regulates DARPP-32 phosphorylation both in vitro and in vivo.

236 opology serves to stabilize the net state of DARPP-32 phosphorylation in response to variation of the

237 DARPP-32 phosphorylation in striatum was selectively inc

238 antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations

239 transgenic mice that allowed the analysis of DARPP-32 phosphorylation selectively in striatonigral an

240 porter knock-out mice show enhanced striatal DARPP-32 phosphorylation, activation of ERK, and inactiv

241 of rM3Ds by clozapine-N-oxide (CNO) induces DARPP-32 phosphorylation, consistent with the known cons

242 phosphorylation states of Thr34- and Ser130-DARPP-32 play important roles in modulating the reinforc

243 DARPP-32 plays a central role in regulating the efficacy

244 ted by variation in PPP1R1B and suggest that DARPP-32 plays a pivotal role in cognitive function and

245 and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) plays a central role in integrating the effect

246 r (BDNF) for 7 d, E13-derived MSNs are 53.7% DARPP-32-positive and 29.0% ARPP-21-positive; E17-derive

247 ARPP-21-positive; E17-derived MSNs are 66.8% DARPP-32-positive and 51.5% ARPP-21-positive.

248 s in our G9-10 LVRs uniquely increased their Darpp-32-positive and Dcx-positive neuron densities.

249 ection persists in iPSC differentiation into DARPP-32-positive neurons in vitro and in vivo.

250 erently possessed fewer mature medium spiny (Darpp-32-positive) neurons (P < 0.001) and fewer immatur

251 or reactivation and (2) an alteration in the DARPP-32/PP1 cascade appears to be a primary event respo

252 The present finding of an altered DARPP-32/PP1 cascade in association with a dysfunction i

253 H10, in intron IV of the gene that codes for DARPP-32 (Ppp1r1b).

254 DARPP-32 promotes resistance of gastric cancer cells to

255 neurons, we measured BDNF-induced levels of DARPP-32 protein and/or mRNA.

256 (STEP) and decreased the phosphorylation of DARPP-32 protein at the Thr-75 site.

257 eroin-induced increase in phosphorylation of DARPP-32 protein in the nucleus accumbens (NAc) and with

258 tion pathways contribute to the induction of DARPP-32 protein levels by BDNF and that the effects are

259 DARPP-32 protein levels were significantly upregulated i

260 ay be partly attributable to reduced D1R and DARPP-32 protein levels.

261 lation states of these inhibitors of ERK and DARPP-32 proteins may thus contribute to the effects of

262 Further experiments showed that DARPP-32 regulates the expression of SRp20 splicing fact

263 ckdown of endogenous DARPP-32 confirmed that DARPP-32 regulates the SRp20-dependent CD44E splicing.

264 we investigated the possible involvement of DARPP-32 regulation in the circadian system using DARPP-

265 ced phosphorylation of Thr-75 and Ser-137 of DARPP-32, respectively.

266 associated with striatal dopamine function (DARPP-32, rs907094, and DRD2, rs6277) were predictive of

267 domain and this interaction is modulated by DARPP-32 Ser97 phosphorylation.

268 -32 and indicates the importance of the cAMP/DARPP-32 signaling cascade in dyskinesia.

269 ulated ion channels and in the D(1) dopamine/DARPP-32 signaling cascade.

270 ular DA levels or signaling through the cAMP/DARPP-32 signaling pathway in either D1- or D2-expressin

271 Conversely, knocking down endogenous DARPP-32 significantly attenuated the splicing activity

272 chnology approach that utilizes gold nanorod-DARPP-32 siRNA complexes (nanoplexes) that target this d

273 els of the PP1 regulatory/targeting proteins DARPP-32, spinophilin, and neurabin were also unchanged.

274 o-overexpression and positive correlation of DARPP-32, SRp20 and CD44E expression levels in human gas

275 The DARPP-32-SRp20 axis has a key role in regulating the CD4

276 ed an evolving neuronal dysfunction (loss of DARPP-32 staining) leading to neurodegeneration (cresyl

277 The amounts of DARPP-32, synapsin I, and the alpha subunit of calcium/c

278 ed the expression of a transcript variant of DARPP-32 (t-DARPP) and ERBB2 in 141 primary tumors and i

279 frequent mRNA and protein overexpression of Darpp-32 than DNA amplification, suggesting that, in add

280 have discovered a novel truncated isoform of DARPP-32 that we named t-DARPP (GenBank accession number

281 ncreases the phosphorylation state of Ser137-DARPP-32, the casein kinase-1 site.

282 d a decreased phosphorylation state at Thr75-DARPP-32, the cyclin-dependent kinase 5 site.

283 point mutations in phosphorylation sites of DARPP-32, the effects of D-amphetamine, LSD, and PCP on

284 Based upon their expression of DARPP-32, the majority of Area X neurons labeled by BrdU

285 an increased phosphorylation state at Thr34-DARPP-32, the protein kinase A site, and a decreased pho

286 rotein) as indicated by elevated FCX phospho-DARPP-32 (Thr(34)).

287 endrite, leads to greater phosphorylation of DARPP-32 Thr34 and AMPA receptor GluA1 Ser845 than when

288 Ca(2+) activates CaN, which dephosphorylates DARPP-32 to dampen Ca(2+) release by eliminating PP1 inh

289 d the association of expression of two major DARPP-32 transcripts, full-length (FL-DARPP-32) and trun

290 G on phosphorylation of Ser-137 or Thr-75 of DARPP-32 was blocked by the phospholipase Cbeta inhibito

291 DARPP-32 was expressed in the retina but not in the IGL

292 We found that the expression of t-DARPP-32 was increased in the DLPFC of patients with sch

293 DARPP-32 was significantly reduced in the dorsolateral p

294 directed against a peptide sequence of human DARPP-32, we immunostained adult rat retinas that were e

295 cells containing the phosphatase inhibitor, DARPP-32, we raised the possibility that these two prote

296 Notably, levels of P-Thr34- and P-Ser130-DARPP-32 were reduced after self-administration of cocai

297 y striatal neurons induced the expression of DARPP-32, whereas a dominant-negative Egr-1 blocked DARP

298 al function was indexed by a gene coding for DARPP-32, which is densely expressed in the striatum whe

299 show that upon phosphorylation of Thr(34) in DARPP-32, which turns DARPP-32 into a potent inhibitor o

300 , full-length (FL-DARPP-32) and truncated (t-DARPP-32), with genetic variants of DARPP-32 in three br